4200 Marathon Boulevard
Suite 200
Austin, TX 78756
United States
512 215 2630
https://www.lumos-pharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 29
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Richard J. Hawkins | CEO & Chairman | 950.32k | N/A | 1949 |
Dr. John C. McKew Ph.D. | Chief Scientific Officer & Pres | 804.98k | N/A | 1964 |
Ms. Lori D. Lawley CPA | CFO & Principal Accounting Officer | 519.11k | N/A | 1984 |
Lisa Miller | Sr. Director of Investor Relations | N/A | N/A | N/A |
Mr. Bradley J. Powers J.D. | Chief Compliance Officer & Gen. Counsel | N/A | N/A | 1979 |
Mr. Carl W. Langren | Consultant | N/A | N/A | 1955 |
Mr. Aaron Schuchart B.B.A., CPA, M.B.A. | Chief Bus. Officer | N/A | N/A | 1965 |
Dr. David B. Karpf B.A., M.D. | Chief Medical Officer | N/A | N/A | 1955 |
Mr. Eddie L. Varnado M.B.A. | VP of Fin. & Corp. Controller | N/A | N/A | N/A |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Lumos Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.